生技药品市场规模、份额、成长分析，按产品、按来源、按应用、按疾病、按製造业、按地区 - 行业预测，2024-2031

2022年生技药品市场规模将达到4,620亿美元，预测期（2024-2031年）复合年增长率为10.40%，从2023年的5100.5亿美元增长到2031年的11255.5亿美元，预计将增长至1000万美元。

生技药品市场正在帮助为许多疾病提供创新和有效的治疗方法，透过有针对性的个人化解决方案彻底改变治疗方法。这些复杂的药物透过重组 DNA 技术等先进的生物技术製程生产，对于治疗癌症、自体免疫疾病和感染疾病等慢性疾病至关重要。市场成长背后的驱动力是此类疾病在全球范围内的日益流行，创造了对生技药品的巨大需求。然而，高成本、製造复杂以及需要特殊储存和运输条件的温度和环境敏感性等挑战使供应链变得复杂。在利用个人化医疗和新兴技术的进步的同时解决这些问题对于市场的未来发展至关重要。

目录

介绍

• 这项研究的目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

关键生技药品市场洞察

• 技术分析
• 市场生态系统
• 专利分析
• Start-Ups分析
• 监管环境
• 创新矩阵
• 主要投资分析
• 关键成功因素
• 竞争程度

生技药品市场：副产品

• 市场概况
• 单株抗体
• 疫苗
• 重组生长因子
• 重组蛋白
• 重组激素
• 重组酵素
• 合成免疫调节剂
• 反义/RNAi
• 治疗药物
• 其他的

生技药品市场：依来源分类

• 市场概况
• 微生物
• 哺乳动物的
• 其他的

生技药品市场：依应用分类

• 市场概况
• 诊断
• 治疗性的
• 蛋白质精製
• 其他的

生技药品市场：依疾病分类

• 肿瘤学
• 心血管
• 免疫疾病
• 感染疾病
• 代谢性疾病

生技药品市场：依製造业分类

• 市场概况
• 外包
• 公司内部

生技药品市场规模：依地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Roche（Switzerland）
• Johnson & Johnson（US）
• AbbVie（US）
• Amgen（US）
• Novartis（Switzerland）
• Pfizer（US）
• Merck & Co.（US）
• AstraZeneca（UK）
• Bristol Myers Squibb（US）
• Sanofi（France）
• Eli Lilly and Company（US）
• Gilead Sciences（US）
• Biogen（US）
• Samsung Biologics（South Korea）
• Novo Nordisk（Denmark）
• Takeda Pharmaceutical Company（Japan）
• Bayer（Germany）
• GlaxoSmithKline（UK）
• Boehringer Ingelheim（Germany）
• Vertex Pharmaceuticals（US）

Biologics Market size was valued at USD 462 Billion in 2022 and is poised to grow from USD 510.05 Billion in 2023 to USD 1125.55 Billion by 2031, at a CAGR of 10.40% during the forecast period (2024-2031).

The biologics market is instrumental in delivering innovative and effective therapies for numerous diseases, significantly transforming treatment approaches with targeted and personalized solutions. These complex drugs, produced through advanced biotechnological processes such as recombinant DNA technology, are essential in managing chronic conditions like cancer, autoimmune disorders, and infectious diseases. The market's growth is driven by the increasing prevalence of such diseases worldwide, creating substantial demand for biologics. However, challenges like high costs, intricate manufacturing, and the need for specialized storage and transportation conditions due to their sensitivity to temperature and environment, complicate the supply chain. Addressing these issues while leveraging advancements in personalized medicine and emerging technologies will be crucial for the market's future development.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biologics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biologics Market Segmental Analysis

The biologics market is segmented by product, source, application, disease, manufacturing, and region. By product, the market can be segmented into Monoclonal Antibodies, Vaccines, Recombinant Growth Factors, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Synthetic Immunomodulators, Antisense & RNAi, Therapeutics, and Others. By source, the market is segmented into microbial, mammalian, and others. By application, the market is segmented into Diagnostic, Therapeutic, Protein Purification, and Others. By disease, the market is segmented into oncology, cardiovascular, immunological diseases, infectious diseases, and metabolic diseases. By manufacturing, the market is segmented into outsourced, and in-house. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Biologics Market

The increasing incidence of chronic diseases like cancer, autoimmune disorders, and diabetes is significantly boosting the biologics market. Biologics provide targeted, personalized treatments, enhancing patient outcomes. In 2022, the FDA approved multiple biologics for cancer treatment, such as Keytruda (pembrolizumab) and Opdivo (nivolumab), underscoring their vital role in modern medicine. These approvals highlight the potential of biologics to revolutionize chronic disease management by offering more precise and effective therapeutic options, thus improving the quality of life for many patients suffering from these severe health conditions.

Restraints in the Biologics Market

The substantial expenses linked to developing, manufacturing, and distributing biologics pose a considerable challenge to the expansion of the market. The intricate manufacturing procedures, rigorous regulatory standards, and costly research and development endeavours collectively drive up the prices of biological medications. As a result, accessibility and affordability are constrained, especially in less affluent regions. The intricate nature of biologic drug production, coupled with stringent regulatory demands and the substantial costs associated with research and development, results in higher prices that can hinder access to these medicines, particularly in developing areas where financial resources are limited.

Market Trends of the Biologics Market

Personalized medicine, or precision medicine, is increasingly prominent in the biologics sector, focusing on customizing treatments according to patients' unique genetic, environmental, and lifestyle characteristics. This approach leverages advancements in genomics and molecular diagnostics to pinpoint specific biomarkers and genetic mutations, which in turn drives the creation of targeted biologic therapies. Drugs such as Keytruda and Herceptin (trastuzumab), designed to target precise genetic mutations in cancer patients, highlight the shift towards personalized medicine. This trend signifies a departure from one-size-fits-all approaches to healthcare, promising more effective and tailored treatments that enhance patient outcomes through a deeper understanding of individual biological nuances.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Biologics Market Insights

• Technology Analysis
• Ecosystem of the Market
• Patent Analysis
• Start-up Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Biologics Market by Product

• Market Overview
• Monoclonal Antibodies
• Vaccines
• Recombinant Growth Factors
• Recombinant Proteins
• Recombinant Hormones
• Recombinant Enzymes
• Synthetic Immunomodulators
• Antisense & RNAi
• Therapeutics
• Others

Biologics Market by Source

• Market Overview
• Microbial
• Mammalian
• Others

Biologics Market by Application

• Market Overview
• Diagnostic
• Therapeutic
• Protein Purification
• Others

Biologics Market by Disease

• Oncology
• Cardiovascular
• Immunological Diseases
• Infectious Diseases
• Metabolic Diseases

Biologics Market by Manufacturing

• Market Overview
• Outsourced
• In-house

Biologics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments